Advancing diagnosis and treatment of Niemann-Pick C disease through biomarker discovery

Exploration of Neuroprotective Therapy

Daniel S. Ory¹  Xuntian Jiang² 

[1] Casma Therapeutics, Cambridge, MA 02139, USA;Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA;

关键词: niemann-pick c;    cholesterol;    biomarkers;    diagnosis;    oxysterol;    bile acids;   

DOI  :  10.37349/ent.2021.00012

来源: DOAJ

【 摘 要 】

Niemann-Pick C disease is a rare neurodegenerative, lysosomal storage disease caused by accumulation of unesterified cholesterol. Diagnosis of the disease is often delayed due to its rarity, the heterogeneous presentation, and the early non-specific symptoms. The discovery of disease-specific biomarkers—cholestane-3β,5α,6β-triol (C-triol), trihydroxycholanic acid glycinate (TCG) and N-palmitoyl-O-phosphocholineserine [PPCS, initially referred to as lysosphingomyelin-509 (lysoSM-509)]—has led to development of non-invasive, blood-based diagnostics. Dissemination of these rapid, sensitive, and specific clinical assays has accelerated diagnosis. Moreover, the superior receiver operating characteristic of the TCG bile acid biomarker and its detection in dried blood spots has also facilitated development of a newborn screen for NPC, which is currently being piloted in New York state. The C-triol, TCG and PPCS biomarkers have also been proved useful for monitoring treatment response in peripheral tissues, but are uninformative with respect to treatment efficacy in the central nervous system (CNS). A major gap for the field is the lack of a validated, non-invasive biomarker to monitor the course of disease and CNS response to therapy.

【 授权许可】

Unknown